182 related articles for article (PubMed ID: 36041055)
21. Postintervention Interleukin-6 (IL-6) Level, Rather than the Pretreatment or Dynamic Changes of IL-6, as an Early Practical Marker of Tumor Response in Hepatocellular Carcinoma Treated with Transarterial Chemoembolization.
Wu Y; Fan W; Xue M; Zhong B; Zhang S; Wang Y; Yao W; Zhao Y; Li J
Oncologist; 2019 Dec; 24(12):e1489-e1495. PubMed ID: 31249138
[TBL] [Abstract][Full Text] [Related]
22. TRIP: a pathological score for transarterial chemoembolization resistance individualized prediction in hepatocellular carcinoma.
Sciarra A; Ronot M; Di Tommaso L; Raschioni C; Castera L; Belghiti J; Bedossa P; Vilgrain V; Roncalli M; Paradis V
Liver Int; 2015 Nov; 35(11):2466-73. PubMed ID: 25865109
[TBL] [Abstract][Full Text] [Related]
23. Renal failure in patients with hepatocellular carcinoma and ascites undergoing transarterial chemoembolization.
Hsu CY; Huang YH; Su CW; Lin HC; Chiang JH; Lee PC; Lee FY; Huo TI; Lee SD
Liver Int; 2010 Jan; 30(1):77-84. PubMed ID: 19818004
[TBL] [Abstract][Full Text] [Related]
24. Incidence, risk factors, and prognosis of acute kidney injury following transarterial chemoembolization in patients with hepatocellular carcinoma: a prospective cohort study.
Hao JF; Zhang LW; Bai JX; Li YJ; Liu JN; Zhang XL; Han JM; Li X; Jiang H; Cao N
Indian J Cancer; 2015 Feb; 51 Suppl 2():e3-8. PubMed ID: 25712839
[TBL] [Abstract][Full Text] [Related]
25. Prospective, randomized, double-blind, multi-center, Phase III clinical study on transarterial chemoembolization (TACE) combined with Sorafenib versus TACE plus placebo in patients with hepatocellular cancer before liver transplantation - HeiLivCa [ISRCTN24081794].
Hoffmann K; Glimm H; Radeleff B; Richter G; Heining C; Schenkel I; Zahlten-Hinguranage A; Schirrmacher P; Schmidt J; Büchler MW; Jaeger D; von Kalle C; Schemmer P
BMC Cancer; 2008 Nov; 8():349. PubMed ID: 19036146
[TBL] [Abstract][Full Text] [Related]
26. N-Acetylcysteine Prevents Post-embolization Syndrome in Patients with Hepatocellular Carcinoma Following Transarterial Chemoembolization.
Siramolpiwat S; Punjachaipornpon T; Pornthisarn B; Vilaichone RK; Chonprasertsuk S; Tangaroonsanti A; Bhanthumkomol P; Phumyen A; Yasiri A; Kaewmanee M
Dig Dis Sci; 2019 Nov; 64(11):3337-3345. PubMed ID: 31073737
[TBL] [Abstract][Full Text] [Related]
27. Tuberculosis reactivation in hepatocellular carcinoma: association with transarterial chemoembolization.
Laake AM; Liappis AP; Guy E; Kerr G; Benator DA
Infect Dis (Lond); 2015 Apr; 47(4):267-70. PubMed ID: 25688446
[TBL] [Abstract][Full Text] [Related]
28. Refractoriness to transarterial chemoembolization in patients with recurrent hepatocellular carcinoma after curative resection.
Jeon MY; Kim HS; Lim TS; Han DH; Kim BK; Park JY; Kim DY; Ahn SH; Choi GH; Choi JS; Han KH; Kim SU
PLoS One; 2019; 14(4):e0214613. PubMed ID: 30947275
[TBL] [Abstract][Full Text] [Related]
29. S100 calcium-binding protein A9 from tumor-associated macrophage enhances cancer stem cell-like properties of hepatocellular carcinoma.
Wei R; Zhu WW; Yu GY; Wang X; Gao C; Zhou X; Lin ZF; Shao WQ; Wang SH; Lu M; Qin LX
Int J Cancer; 2021 Mar; 148(5):1233-1244. PubMed ID: 33205453
[TBL] [Abstract][Full Text] [Related]
30. Sorafenib With and Without Transarterial Chemoembolization for Advanced Hepatocellular Carcinoma With Main Portal Vein Tumor Thrombosis: A Retrospective Analysis.
Zhang Y; Fan W; Wang Y; Lu L; Fu S; Yang J; Huang Y; Yao W; Li J
Oncologist; 2015 Dec; 20(12):1417-24. PubMed ID: 26446238
[TBL] [Abstract][Full Text] [Related]
31. Safety and Efficacy of Transarterial Radioembolization Combined with Chemoembolization for Bilobar Hepatocellular Carcinoma: A Single-Center Retrospective Study.
Kwon JH; Kim GM; Han K; Won JY; Kim MD; Lee DY; Lee J; Choi W; Kim YS; Kim DY; Han KH
Cardiovasc Intervent Radiol; 2018 Mar; 41(3):459-465. PubMed ID: 29067511
[TBL] [Abstract][Full Text] [Related]
32. Liver failure after transarterial chemoembolization for patients with hepatocellular carcinoma and ascites: incidence, risk factors, and prognostic prediction.
Hsin IF; Hsu CY; Huang HC; Huang YH; Lin HC; Lee RC; Chiang JH; Lee FY; Huo TI; Lee SD
J Clin Gastroenterol; 2011 Jul; 45(6):556-62. PubMed ID: 21666547
[TBL] [Abstract][Full Text] [Related]
33. Changes in the Peripheral Blood Treg Cell Proportion in Hepatocellular Carcinoma Patients After Transarterial Chemoembolization With Microparticles.
Ren Z; Yue Y; Zhang Y; Dong J; Liu Y; Yang X; Lin X; Zhao X; Wei Z; Zheng Y; Wang T
Front Immunol; 2021; 12():624789. PubMed ID: 33717135
[TBL] [Abstract][Full Text] [Related]
34. Short-term efficacy and safety of callispheres drug-loaded microsphere embolization in primary hepatocellular carcinoma.
Li J; Wang N; Shi C; Liu Q; Song J; Ye X
J Cancer Res Ther; 2021 Jul; 17(3):733-739. PubMed ID: 34269307
[TBL] [Abstract][Full Text] [Related]
35. Poor prognosis for hepatocellular carcinoma with transarterial chemoembolization pre-transplantation: retrospective analysis.
Li HL; Ji WB; Zhao R; Duan WD; Chen YW; Wang XQ; Yu Q; Luo Y; Dong JH
World J Gastroenterol; 2015 Mar; 21(12):3599-606. PubMed ID: 25834326
[TBL] [Abstract][Full Text] [Related]
36. Long-Term Outcomes of Transarterial Chemoembolization Combined with Radiofrequency Ablation Versus Transarterial Chemoembolization Alone for Recurrent Hepatocellular Carcinoma After Surgical Resection.
Song Q; Ren W; Fan L; Zhao M; Mao L; Jiang S; Zhao C; Cui Y
Dig Dis Sci; 2020 Apr; 65(4):1266-1275. PubMed ID: 31312995
[TBL] [Abstract][Full Text] [Related]
37. Trends and outcomes of transarterial chemoembolization in hepatocellular carcinoma: a national survey.
Mumtaz K; Patel N; Modi RM; Patel V; Hinton A; Hanje J; Black SM; Krishna S
Hepatobiliary Pancreat Dis Int; 2017 Dec; 16(6):624-630. PubMed ID: 29291782
[TBL] [Abstract][Full Text] [Related]
38. Predictive value of recurrence for serum hypoxia inducible factor-1α C-reaction protein in hepatocellular carcinoma patients after transcatheter arterial chemoembolization.
Jing Q; Jianyong L; Jiming Y; Shuren L; Rui W; Wei L
Indian J Cancer; 2015 Dec; 52 Suppl 2():e105-6. PubMed ID: 26728665
[TBL] [Abstract][Full Text] [Related]
39. Thermal Ablation Versus Stereotactic Body Radiotherapy After Transarterial Chemoembolization for Inoperable Hepatocellular Carcinoma: A Propensity Score-Weighted Analysis.
Nabavizadeh N; Jahangiri Y; Rahmani R; Tomozawa Y; Geeratikun Y; Chen Y; Hung A; Degnin C; Farsad K
AJR Am J Roentgenol; 2021 Sep; 217(3):691-698. PubMed ID: 32997517
[No Abstract] [Full Text] [Related]
40. Comprehensive predictive factors for CalliSpheres® microspheres (CSM) drug-eluting bead-transarterial chemoembolization and conventional transarterial chemoembolization on treatment response and survival in hepatocellular carcinoma patients.
Chen C; Qiu H; Yao Y; Zhang Z; Ma C; Ma Y; Zhao C; Xiang H; Zhao H; Zheng C; Xiong B; Li H; Long Q; Zhou J; Luo C; Hu H
Clin Res Hepatol Gastroenterol; 2021 Mar; 45(2):101460. PubMed ID: 32593695
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
